Galderma Laboratories Inc.

Galderma Pharma S.a.

Jack A DeJovin

Michael Graeber

Thomas M Rossi

Isabelle Jean DeJovin

Christian Loesche

Matthew James Leoni

Philip Freidenreich

Yin-sang Liu

Christopher Powala

Methods and kits for treating or preventing psoriasis or a symptom associated with psoriasis in a subject are described. The methods involve topical applications to the subject a therapeutically effective amount of an &#x3b1;2 adrenergic receptor agonist.

Method for treating psoriasis

In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: 

Compounds, formulations, and methods for treating or preventing inflammatory skin disorders

In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R, R, and Ris independently hydrogen, hologen, alkyl, or alkoxy; each of Rand Ris independently hydrogen, alkyl, or alkoxy; and each of Rand Ris independently hydrogen, nitro, alkyl, or alkoxy;wherein each of A, A, and Ais independently hydrogen or alkyl; and Ais independently hydrogen or hydroxy; andwherein each of B, B, and Bis independently hydrogen, hydroxy, or alkoxy; and each of Band Bis independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.

Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one &#x3b1;-adrenergic receptor agonist and a pharmaceutically acceptable carrier.

Methods and compositions for treating or preventing erythema

Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an &#x3b1;2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly reduce skin sagging, creasing and/or wrinkling for at least about 8 hours.

Compounds, formulations and methods for reducing skin wrinkles, creasing and sagging

In methods, compounds, and topical formulations for treatment of inflammatory skin disorders incorporating compounds represented by the formulas below: wherein each of R, R, and Ris independently hydrogen, hologen, alkyl, or alkoxy;each of Rand Ris independently hydrogen, alkyl, or alkoxy; and each of Rand Ris independently hydrogen, nitro, alkyl, or alkoxy;wherein each of A, A, and Ais independently hydrogen or alkyl; and Ais independently hydrogen or hydroxy; andwherein each of B, B, and Bis independently hydrogen, hydroxy, or alkoxy; and each of Band Bis independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat inflammatory skin disorders and the symptoms associated therewith.

Methods and kits for treating or preventing psoriasis or a symptom associated with psoriasis in a subject are described. The methods involve topical applications to the subject a therapeutically effective amount of an &#x3b1;2 adrenergic receptor agonist, such as brimonidine.

Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an &#x3b1;-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours.

Compounds, formulations, and methods for ameliorating telangiectasis

Compounds, formulations, and methods for ameliorating telangiectasias

In methods, compounds, and topical formulations for treatment of rosacea incorporating compounds represented by the formulas below: wherein each of R, R, and Ris independently hydrogen, hologen, alkyl, or alkoxy;each of Rand Ris independently hydrogen, alkyl, or alkoxy; and each of Rand Ris independently hydrogen, nitro, alkyl, or alkoxy;wherein each of A, A, and Ais independently hydrogen or alkyl; and Ais independently hydrogen or hydroxy; andwherein each of B, B, and Bis independently hydrogen, hydroxy, or alkoxy; and each of Band Bis independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat rosacea and its symptoms.

Growing community of inventors

New Brunswick, NJ, United States of America

Jack A DeJovin